Anxiety disorders are prevalent and impairing, and they are a leading cause of disability-adjusted life-years worldwide.1 The estimated 12-month prevalence of anxiety disorders among US adults is approximately 10%.2 Yet since 2007, no new anxiolytics have been approved by the US Food and Drug Administration (FDA). Although new anxiety treatments are needed, patients can benefit from existing pharmacological and psychosocial therapies3 delivered using current best practices.
Stein MB, Craske MG. Treating Anxiety in 2017Optimizing Care to Improve Outcomes. JAMA. 2017;318(3):235–236. doi:10.1001/jama.2017.6996